ArticleJournal of virology2025
Engineering a TGEV S-trimer chimera with PEDV D0-NTD generates potent neutralizing antibodies against both viruses.
Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Evaluating the Immunogenicity of a RecombinantBiology · 2026Article
- Development of a ferritin-based subunit nanoparticle vaccine targeting the S-RBD of porcine transmissible gastroenteritis virus.Frontiers in veterinary science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Porcine epidemic diarrhea virus (PEDV) and transmissible gastroenteritis virus (TGEV), two economically devastating swine enteric coronaviruses, persistently threaten global pork production via severe clinical morbidity. Vaccination is the most effective means to prevent morbidity and mortality caused by porcine enteric coronavirus infection. Hence, the development of an effective and safe vaccination strategy to protect against both PEDV and TGEV infections is urgently needed. Here, we designed and produced trimerized full-length PEDV and TGEV spike (S) proteins using an efficient mammalian expression vector system in HEK293F cells and reported that compared with the PEDV spike protein (2
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.